Angion Biomedica Corp
NASDAQ:ANGN 3:30:49 PM EDT
| Market Cap (Intraday) | 51.23M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $1.75 |
| 50-Day MA | $1.51 |
| 200-Day MA | $3.43 |
Angion Biomedica Corp Stock, NASDAQ:ANGN
51 Charles Lindbergh Boulevard, Suite 1200, Uniondale, New York 11553
United States of America
Phone: +1.415.655.4899
Number of Employees: 71
Description
Angion Biomedica Corp. operates as a biopharmaceutical company. The firm focuses on the discovery and development of novel therapeutic agents to address acute organ injuries and fibrotic diseases. Its product pipeline includes ANG-3777, ANG-3070, ROCK2 Inhibitor and CYP11B2 Inhibitors. The company was founded by Itzhak D. Goldberg on April 06, 1998 and is headquartered in Uniondale, NY.